Alzheimer’s drug donanemab helps most when taken at earliest disease stage, study finds

Sara Reardon

Nature, 2023, vol. 619, issue 7971, 682-683

Abstract: But the drug, an antibody that attacks the protein amyloid, does not work as well in people with more advanced disease.

Keywords: Alzheimer's disease; Neurodegeneration (search for similar items in EconPapers)
Date: 2023
References: Add references at CitEc
Citations:

Downloads: (external link)
https://www.nature.com/articles/d41586-023-02321-1 Abstract (text/html)
Access to the full text of the articles in this series is restricted.

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:nat:nature:v:619:y:2023:i:7971:d:10.1038_d41586-023-02321-1

Ordering information: This journal article can be ordered from
https://www.nature.com/

DOI: 10.1038/d41586-023-02321-1

Nature is currently edited by Magdalena Skipper

More articles in Nature from Nature
Bibliographic data for series maintained by Sonal Shukla () and Springer Nature Abstracting and Indexing ().